BIOGEN AVONEX REVENUES ARE $56.4 MIL. IN QUARTER; AMGEN PREDICTS SECOND HALF EPOGEN GROWTH OF 15%, SAME AS FIRST; GENENTECH ACTIVASE MARKET SHARE DIPS
Executive Summary
Biogen's multiple sclerosis therapy Avonex generated revenues of $56.4 mil. in the second quarter, the company reported. About 30,000 patients are taking the drug worldwide, Biogen said.